- The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutions
- Through an exclusive partnership with Applied Pharmaceutical Innovations, the company has access to a Health Canada Scheduled 1 Drugs and Substances Dealer’s License
- Mydecine has a five-year master collaboration research agreement with Johns Hopkins University to research novel psychedelic therapies for mental health and addiction disorders
- Research out of Johns Hopkins University has shown promising efficacy data using psilocybin as a smoking cessation treatment with an abstinence rate of 80% at six months
- Mydecine is supplying its lead drug candidate, MYCO-001, for a multi-site NIDA (National Institute on Drug Abuse) grant-funded smoking cessation study, marking the first time in over 50 years that the U.S. government has funded a study of a psychedelic compound
- The company utilizes established drug development infrastructure, and it offers telemedicine and technology solutions through the Mindleap 2.0 platform
- Mydecine is guided by an experienced leadership team and a world-renowned medical & scientific advisory board
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction. Founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovations in the mental health and therapeutic treatment environments, Mydecine is dedicated to efficiently developing innovative first- and second-generation novel therapeutics to treat PTSD, addiction and other mental health disorders.
Mydecine’s business model combines clinical trials and data outcome, technology and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine aims to responsibly fast-track the development of new medicines across its platforms, ultimately changing the way we treat mental health disorders. The company seeks to bridge the gap between the needs of patients and what the mental health care system currently provides.
Mydecine Innovations Group is headquartered in Denver with international offices in Canada and Europe.
Research and Technology
The invention and development of novel psychedelic and non-psychedelic molecules for medical use is an important part of Mydecine’s research strategy. The company uses molecules found in nature as building blocks to create improved second-generation drugs. This portfolio of new drugs represents major improvements to existing natural products and synthetics, including enhanced safety, efficacy, stability and dosing, as well as reduced side effects.
The goal of creating these improved second-generation compounds is to enable safer, more effective treatments for patients, along with improved management of dosage and drug behavior for clinicians. Mydecine believes the multibillion-dollar market for mental health and addiction disorder medicines will soon be disrupted amid a resurgence of the study into psychedelics and data showing the immense benefits of these forms of medicine.
The company currently has four lead drug candidates which include various enhancements such as improved controllability, delivery mechanisms, safety, stability and shelf-life. The drug candidates are in clinical trials or in pre-trial stage as potential treatments to aid PTSD, substance abuse and smoking cessation.
Mindleap Health is a wholly owned subsidiary of Mydecine. The Mindleap platform is a virtual community that aims to foster the conscious and responsible adoption of psychedelic medicine into inner wellness. Users access the platform through the Mindleap app. Mindleap provides users with inner wellness resources to assist them in their daily mental-health journeys. The platform also seeks to support the conscious and trustworthy adoption of psychedelics into a widely accepted approach to mental health and inner wellness.
Market Outlook
The global smoking cessation market is expected to reach $63.99 billion by 2026, growing at a CAGR of 16.9 percent from 2018 to 2026. The market for psychedelic therapeutics is in its very early stages. Estimates of current market value and forecasts of expected value in future years are all over the map. Market forecasts range from $6.5 billion by 2030 with a CAGR of 15 percent, to more than $69 billion as soon as 2025, at a CAGR of 8.2 percent. What is clear is that interest in psychedelic therapeutic drugs is expanding rapidly.
Management Team
Joshua Bartch is Chief Executive Officer and Chairman of Mydecine Innovations Group. He is an experienced entrepreneur who co-founded AudioTranscriptionist.com and founded Denver-based dispensary Doctors Orders in 2009. He also founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the USA’s most significant and sophisticated legal cannabis wholesale platform.
Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, is the Chief Medical Officer of Mydecine. He was formerly Chief of Psychiatry for the Canadian Armed Forces, retiring in 2021 with the rank of colonel after 31 years of service. He began his career as a general duty medical officer and flight surgeon and spent his final 20 years of service as a psychiatrist. He maintains academic appointments at Dalhousie University and The University of Ottawa. He is the inaugural CF Brigadier Jonathan C. Meakins CBE, RCMAC, Chair in Military Mental Health at the Royal Ottawa Hospital.
Robert Roscow is Chief Scientific Officer of Mydecine. As a geneticist, he has spent his academic and professional careers looking for valuable and unique medicinal molecules found in nature. His innovations were applied at Canopy Growth and ebbu, where he ran those companies’ genetics divisions. He has leveraged his expertise to maximize industrial production of cannabinoids in a pharmacological context, resulting in multiple patent filings.
Damon Michaels is Chief Operating Officer of Mydecine. He previously consulted for various hemp businesses through his company, Emerald Baron. Before that, he served as GM for ebbu, the leading multi-platform cannabinoid research and technology firm based in Colorado. He has held leading roles with multiple large brands throughout the cannabis vertical. He also developed a national snowboard brand.
For more information, visit the company’s website at www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment